Ahead of an expected U.S. launch in the second half of 2017, Valeant has Siliq price approved: it is set at $3500 per month or $42,000 per year.
The price of Siliq was decided by its Patient Access and Pricing Committee, set up a year ago, to ensure the company’s drugs are affordable and prices comply with relevant laws, regulations and guidance. Valeant said is the lowest priced injectable biologic psoriasis treatment currently on the market.
Siliq, an anti-inflammatory has been approved as a treatment for moderate-to-severe plaque psoriasis, in mid-February even if asked for a label black box warning calling attention to the risk of suicidal thoughts and behavior.
A part from Taltz and Cosentyx, Siliq will also compete with other classes of drugs used to treat psoriasis such as Amgen Inc’s Enbrel, Johnson & Johnson’s Remicade and AbbVie Inc’s Humira.
The Canadian drugmaker’s U.S.-listed shares were up about 1% after the annoucement.